期刊文献+

All about Peyronie’s disease 被引量:4

下载PDF
导出
摘要 Peyronie’s disease(PD)is an acquired connective tissue disorder of the tunica albuginea of the corpus cavernosum,characterized by excessive fibrosis and plaque formation.PD can result in significant physical and psychological morbidity;as it may prevent intercourse and cause adverse impacts on partner relationships.The exact etiology and pathophysiology remain unclear,and many misconceptions about the disease associations,course and treatment exist.The disease has two distinct stages.The acute stage is characterized by pain,and disease may progress during this stage.Non-surgical managements at this stage aim to alleviate pain and stabilize the disease.Results for non-surgical treatment are often conflicting.The chronic stage occurs 6e12 months later,where pain disappears and the deformity stabilizes.Surgical treatment is reserved for significant deformity or with inability to penetrative intercourse.The choice of the surgical technique depends on the length of the penis,degree of deformity,erectile function,patients’expectations and surgeon’s preference.
出处 《Asian Journal of Urology》 2015年第2期70-78,共9页 亚洲泌尿外科杂志(英文)
  • 相关文献

参考文献1

二级参考文献28

  • 1Mulhall JP, Creech SD, Boorjian SA, Ghaly S, Kim FD etal. Subjective and objective analysis of the prevalence of Peyronie's disease in a population of men presenting for prostate cancer screening. J Uro12004; 171: 2350-3.
  • 2Schwarzer U, Sommer F, KIotz T, Braun M, Reifenrath 13 et al. The prevalence of Peyronie's disease= results of a large survey. BJU Int 2001; 88:727-30.
  • 3Safarinejad MR. Therapeutic effects of colchicine in the management of Peyronie's disease: a randomized double-blind, placebo-controlled study, Int J Impot Res 2004; 16:238-43.
  • 4Hellstrom W J, Kendirci M, Matern R, Cockerham Y, Myers Let al. Single-blind, multicenter, placebo controlled, parallel study to assess the safety and efficacy of intralesional interferon alpha-2B for minimally invasive treatment for Peyronie's disease. J Uro12006; 176: 394-8.
  • 5Inal T, Tokatli Z, Akand M, Ozdiler E, Yaman O. Effect of intralesional interferon-alpha 2b combined with oral vitamin E for treatment of early stage Peyronie's disease: a randomized and prospective study. Urolo~2006; 67: 1038-42,.
  • 6Cavallini G, Biagiotti G, Koverech A, Vitali G. Oral propionyI-L-carnitine and intraplaque verapamil in the therapy of advanced and resistant Peyronie's disease. BJU Int 2002; 89: 895-900.
  • 7Greenfield JM, Shah S J, Levine LA. Verapamil versus saline in electromotive drug administration for Peyronie's diseasea double-blind, placebo controlled trial. J Urol 2007; 177: 972-5.
  • 8Rehman J, Benet A, Melman A. Use of intralesional verapamil to dissolve Peyronie's disease plaque: a long-term single-blind study. Urolo67y 1998:51: 620-6.
  • 9Safarinejad MR, Hosseini SY, Kolahi AA. Comparison of vitamin E and propionyI-L- carnitine, separately or in combination, in patients with early chronic Peyronie's disease; a double-blind, placebo controlled, randomized study. J Uro12007; 178:1398-403; discussion 403.
  • 10Pryor J, Akkus E, Alter G, Jordan G, Lebret T etal. Peyronie's disease. J Sex Med2004; 1: 110-5.

共引文献2

同被引文献13

引证文献4

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部